Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

CSL continues to provide medicines to patients around the world.

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.

CSL Limited's statement on Coronavirus

Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than 60,000 employees working in a range of industries.

Chief Executive Officer and Managing Director Paul Perreault presented the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.

Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing.

CSL statement in response to media reports on case against Joseph Chiao

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination

Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.

MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long STEM literacy.

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, incorporating CSL’s Global Hub for Research and Translational Medicine.

CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into why so many people die from infection following stroke and how we might develop better vaccines against diseases such as tuberculosis.

CSL today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.

Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index

$2.5 Million Funding Available to Australian Biomedical Researchers